TF and neoplasm: Furthermore, the PTX formulated in the non-targeted L-APVNs and targeted Tf-L-APVNs showed significant (P < 0.05) decrease in tumor size indicating the therapeutic advantage of Tf conjugation, and of Tf as a targeting ligand.